Ofatumumab is currently not available.
Our suppliers are constantly updating their product inventory and availability status. If you would like us to notify you when Ofatumumab becomes available, please fill out the form below.
*We value your privacy! We will never give, lease, sell or otherwise disclose your personal information. Period!
Information about SaveRxCanada.to
List of countries where we can ship Ofatumumab:
Latest news releases on Ofatumumab:
Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular loops.
Product details for Arzerra; Name: Arzerra: Agency product number: EMEA/H/C/001131: Active substance: ofatumumab. International non-proprietary name (INN) or common name
Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of ...
Medscape - CLL dosing for Arzerra (ofatumumab), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and ...
Discover ARZERRA® (ofatumumab), approved for 4 CLL treatment indications. Find dosing information & patient resources. See Important Safety Information & BOXED WARNING.
Original Article. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. John C. Byrd, M.D., Jennifer R. Brown, M.D., Ph.D., Susan O'Brien, M.D ...
FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs ...
Correspondence. Ofatumumab for Rituximab-Resistant Nephrotic Syndrome. N Engl J Med 2014; 370:1268-1270 March 27, 2014 DOI: 10.1056/NEJMc1308488
Arzerra 100mg & 1000mg concentrate for solution for infusion - Summary of Product Characteristics (SPC) by Novartis Pharmaceuticals UK Ltd
INDICATIONS. RITUXAN ® (rituximab) is indicated for the treatment of: Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in ...